John L. Perez

24.5k total citations · 1 hit paper
64 papers, 3.3k citations indexed

About

John L. Perez is a scholar working on Epidemiology, Microbiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, John L. Perez has authored 64 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Epidemiology, 44 papers in Microbiology and 10 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in John L. Perez's work include Bacterial Infections and Vaccines (44 papers), Pneumonia and Respiratory Infections (43 papers) and Virology and Viral Diseases (10 papers). John L. Perez is often cited by papers focused on Bacterial Infections and Vaccines (44 papers), Pneumonia and Respiratory Infections (43 papers) and Virology and Viral Diseases (10 papers). John L. Perez collaborates with scholars based in United States, United Kingdom and Belgium. John L. Perez's co-authors include John T. Sharp, Ferdinand C. Breedveld, G Spencer-Green, Arthur F. Kavanaugh, Karel Pavelká, Michael H. Weisman, Ronald van Vollenhoven, Stanley Cohen, Itzhak Kronzon and Robin S. Freedberg and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and Clinical Infectious Diseases.

In The Last Decade

John L. Perez

63 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

2005 1.4k citations John L. Perez et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John L. Perez United States	28	1.4k	1.1k	908	684	450	64	3.3k
Wolfgang Schlumberger Germany	27	727 0.5×	768 0.7×	67 0.1×	119 0.2×	356 0.8×	63	2.8k
Andrew Keat United Kingdom	30	1.7k 1.2×	393 0.3×	276 0.3×	612 0.9×	61 0.1×	93	2.7k
Anna Beutler United States	27	2.6k 1.8×	313 0.3×	108 0.1×	1.3k 1.9×	54 0.1×	53	3.5k
Patrice Morel France	35	671 0.5×	1.3k 1.1×	209 0.2×	247 0.4×	130 0.3×	123	3.3k
Martin Stern Switzerland	36	374 0.3×	976 0.8×	36 0.0×	1.7k 2.5×	520 1.2×	135	5.0k
R. von Essen Finland	24	790 0.6×	605 0.5×	73 0.1×	269 0.4×	70 0.2×	58	2.4k
Aris Antsaklis Greece	33	268 0.2×	708 0.6×	68 0.1×	122 0.2×	418 0.9×	208	4.2k
Frank B. Vasey United States	27	1.0k 0.7×	296 0.3×	65 0.1×	321 0.5×	206 0.5×	63	2.0k
John Kasznica United States	19	705 0.5×	1.4k 1.2×	21 0.0×	319 0.5×	429 1.0×	50	3.5k
A. Hot France	35	907 0.6×	532 0.5×	18 0.0×	771 1.1×	650 1.4×	146	3.2k

Countries citing papers authored by John L. Perez

Since Specialization

Citations

This map shows the geographic impact of John L. Perez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L. Perez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L. Perez more than expected).

Fields of papers citing papers by John L. Perez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John L. Perez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L. Perez. The network helps show where John L. Perez may publish in the future.

Co-authorship network of co-authors of John L. Perez

This figure shows the co-authorship network connecting the top 25 collaborators of John L. Perez. A scholar is included among the top collaborators of John L. Perez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John L. Perez. John L. Perez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Beeslaar, Johannes, Susan Mather, Judith Absalon, et al.. (2022). Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 40(12). 1872–1878. 2 indexed citations

Marshall, Helen, Timo Vesikari, Peter Richmond, et al.. (2022). Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1–9 years: two phase 2 randomised, controlled, observer-blinded studies. The Lancet Infectious Diseases. 23(1). 103–116. 4 indexed citations

Thomas, Stephen J., John L. Perez, Stephen Lockhart, et al.. (2021). 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine. Annals of Oncology. 32. S1129–S1129. 9 indexed citations

Østergaard, Lars, Timo Vesikari, Shelly Senders, et al.. (2021). Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months. Vaccine. 39(32). 4545–4554. 7 indexed citations

Borja-Tabora, Charissa, Paula Peyrani, Chris Webber, et al.. (2020). A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. BMC Infectious Diseases. 20(1). 426–426. 10 indexed citations

Beeslaar, Johannes, Judith Absalon, Annaliesa S. Anderson, et al.. (2020). MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies. Infectious Diseases and Therapy. 9(3). 641–656. 4 indexed citations

Beeslaar, Johannes, Paula Peyrani, Judith Absalon, et al.. (2020). Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data. Infectious Diseases and Therapy. 9(3). 625–639. 3 indexed citations

Harris, Shannon L., Cuiwen Tan, John L. Perez, et al.. (2020). Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine. npj Vaccines. 5(1). 8–8. 11 indexed citations

Beeslaar, Johannes, Judith Absalon, Paul Balmer, et al.. (2018). Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults. Vaccine. 36(28). 4004–4013. 6 indexed citations

10.

Taha, Muhamed‐Kheir, Paul Liberator, Ala‐Eddine Deghmane, et al.. (2017). Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine. 35(11). 1530–1537. 23 indexed citations

11.

Donald, Robert G. K., Hao Li, Paul Liberator, et al.. (2016). Meningococcal serogroup B vaccines: Estimating breadth of coverage. Human Vaccines & Immunotherapeutics. 13(2). 255–265. 39 indexed citations

12.

Østergaard, Lars, Gregg Lucksinger, Judith Absalon, et al.. (2016). A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. Vaccine. 34(12). 1465–1471. 19 indexed citations

13.

Vesikari, Timo, Lars Østergaard, Javier Díez‐Domingo, et al.. (2015). Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. Journal of the Pediatric Infectious Diseases Society. 5(2). 152–160. 45 indexed citations

14.

Zlotnick, Gary W., Thomas R. Jones, Paul Liberator, et al.. (2014). The Discovery and Development of a Novel Vaccine to Protect againstNeisseria meningitidisSerogroup B Disease. Human Vaccines & Immunotherapeutics. 11(1). 5–13. 69 indexed citations

15.

Martinón‐Torres, Federico, et al.. (2014). A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants. Vaccine. 32(40). 5206–5211. 27 indexed citations

16.

Richmond, Peter, Helen Marshall, Michael D. Nissen, et al.. (2012). Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases. 12(8). 597–607. 108 indexed citations

17.

Burmester, Gerd R, Philip J. Mease, Ben A. C. Dijkmans, et al.. (2009). Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases. 68(12). 1863–1869. 159 indexed citations

18.

Perez, John L. & Richard D. Moore. (2003). Greater Effect of Highly Active Antiretroviral Therapy on Survival in People Aged ⩾50 Years Compared with Younger People in an Urban Observational Cohort. Clinical Infectious Diseases. 36(2). 212–218. 87 indexed citations

19.

Powell, David, Paul A. Tunick, Barry P. Rosenzweig, et al.. (2000). Aortic Valve Replacement in Patients With Aortic Stenosis and Severe Left Ventricular Dysfunction. Archives of Internal Medicine. 160(9). 1337–1337. 80 indexed citations

20.

Tunick, Paul A., Rachel Lampert, John L. Perez, & Itzhak Kronzon. (1990). Effect of mitral regurgitation on the left ventricular outflow pressure gradient in obstructive hypertrophic cardiomyopathy. The American Journal of Cardiology. 66(17). 1271–1273. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact